MA49257A - Anticorps anti-trkb - Google Patents

Anticorps anti-trkb

Info

Publication number
MA49257A
MA49257A MA049257A MA49257A MA49257A MA 49257 A MA49257 A MA 49257A MA 049257 A MA049257 A MA 049257A MA 49257 A MA49257 A MA 49257A MA 49257 A MA49257 A MA 49257A
Authority
MA
Morocco
Prior art keywords
trkb antibodies
trkb
antibodies
Prior art date
Application number
MA049257A
Other languages
English (en)
Inventor
Remko Alexander Bakker
Sebastian Bandholtz
Peter Michael Benz
Michael Dziegelewski
Lore Florin
Rolf Herrmann
Cynthia Hess Kenny
Sarah Low
Holger Rosenbrock
Sanjaya Singh
Heiko Friedrich Stahl
Sathyadevi Venkataramani
Vladimir Voynov
Haiguang Xiao
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA49257A publication Critical patent/MA49257A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA049257A 2017-06-09 2018-06-08 Anticorps anti-trkb MA49257A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17175122 2017-06-09

Publications (1)

Publication Number Publication Date
MA49257A true MA49257A (fr) 2020-04-15

Family

ID=59034551

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049257A MA49257A (fr) 2017-06-09 2018-06-08 Anticorps anti-trkb

Country Status (22)

Country Link
US (3) US10793634B2 (fr)
EP (1) EP3635004A1 (fr)
JP (2) JP7267208B2 (fr)
KR (1) KR20200017421A (fr)
CN (1) CN110719916B (fr)
AR (1) AR112602A1 (fr)
AU (1) AU2018279184B2 (fr)
BR (1) BR112019023742A2 (fr)
CA (1) CA3063965A1 (fr)
CL (1) CL2019003557A1 (fr)
CO (1) CO2019013718A2 (fr)
EA (1) EA201992883A1 (fr)
IL (1) IL271067B2 (fr)
MA (1) MA49257A (fr)
MX (1) MX2019014714A (fr)
MY (1) MY202315A (fr)
PE (1) PE20200173A1 (fr)
PH (1) PH12019502694A1 (fr)
SG (1) SG11201911814UA (fr)
TW (2) TW202342100A (fr)
UA (1) UA127967C2 (fr)
WO (1) WO2018224630A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11198726B2 (en) * 2017-06-02 2021-12-14 Boerhinger Ingelheim International Gmbh Anti-cancer combination therapy
CR20220206A (es) 2019-11-11 2022-06-16 Boehringer Ingelheim Int Agonistas del receptor npy2
JP7661478B2 (ja) 2020-08-07 2025-04-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 可溶性ｎｐｙ２受容体アゴニスト
EP4232474A1 (fr) 2020-10-21 2023-08-30 Boehringer Ingelheim International GmbH Molécules de liaison anti-vegf et anti-trkb bispécifiques pour le traitement de maladies oculaires
WO2023125485A1 (fr) * 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited Anticorps trkb et son application
WO2025062271A1 (fr) * 2023-09-19 2025-03-27 Signorile Pietro Giulio Anticorps dirigés contre l'endométriose
CN119841947B (zh) * 2024-12-17 2026-04-17 河南农业大学 十二指肠贾第虫cwp2蛋白的单克隆抗体及配对单克隆抗体及应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP1400536A1 (fr) 1991-06-14 2004-03-24 Genentech Inc. Procédé pour fabriquer des anticorps humanisés
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
GT200600240A (es) * 2005-06-06 2007-03-14 Anticuerpos monoclonales anti-trkb y usos de los mismos
EP2087007A2 (fr) * 2006-11-09 2009-08-12 Irm Llc Anticorps d'agonistes de trkb et leurs utilisations
WO2008078179A1 (fr) 2006-12-20 2008-07-03 Rinat Neuroscience Corporation Agonistes de trkb pour le traitement des troubles auto-immunitaires
WO2009048605A1 (fr) 2007-10-11 2009-04-16 Biogen Idec Ma Inc. Procédés destinés à traiter la neuropathie optique induite par la pression, à prévenir la dégénérescence neurale et à promouvoir la survie des cellules neuronales par le biais de l'administration d'antagonistes lingo-1 et d'agonistes trkb
EP2214706A1 (fr) 2007-10-23 2010-08-11 Novartis AG Utilisation d'anticorps trkb pour le traitement de troubles respiratoires
PE20091326A1 (es) 2008-01-17 2009-09-18 Irm Llc Anticuerpos anti-trkb mejorados
EP2252633B9 (fr) 2008-02-04 2014-02-19 Lay Line Genomics S.P.A. Anticorps anti-trka et leurs dérivés
WO2010014613A2 (fr) 2008-07-28 2010-02-04 Emory University Traitement de divers troubles mettant en oeuvre des agonistes trkb
WO2010086828A2 (fr) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Anticorps monoclonaux agonistes anti-trkb
WO2011103667A1 (fr) * 2010-02-26 2011-09-01 6452728 Canada Inc. Anticorps agonistes des récepteurs trkb et leurs utilisations
EP2579870B1 (fr) 2010-06-09 2018-02-14 Emory University Agonistes trkb et leurs procédés d'utilisation
US9200080B2 (en) 2010-09-03 2015-12-01 Horacio Uri Saragovi Agonistic antibodies to TrkC receptors and uses thereof
GB2491106A (en) 2011-05-18 2012-11-28 Univ Basel Antibodies against tropomyosin-related kinase B receptors
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
KR20180037994A (ko) 2015-07-28 2018-04-13 오토노미, 인코포레이티드 TrkB 또는 TrkC 아고니스트 조성물 및 귀 병태의 치료 방법
JP7039468B2 (ja) 2015-11-17 2022-03-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド 神経およびその他の障害の処置のための結合アゴニスト
US11066474B2 (en) 2017-11-30 2021-07-20 Regeneron Pharmaceuticals, Inc. Anti-TrkB monoclonal antibodies and methods of use

Also Published As

Publication number Publication date
JP7267208B2 (ja) 2023-05-01
JP2020522270A (ja) 2020-07-30
US20200399378A1 (en) 2020-12-24
TWI808086B (zh) 2023-07-11
MX2019014714A (es) 2020-02-07
JP7505084B2 (ja) 2024-06-24
TW202342100A (zh) 2023-11-01
CA3063965A1 (fr) 2018-12-13
WO2018224630A1 (fr) 2018-12-13
AU2018279184B2 (en) 2024-08-01
CN110719916B (zh) 2024-05-31
US20180355046A1 (en) 2018-12-13
AR112602A1 (es) 2019-11-20
EP3635004A1 (fr) 2020-04-15
EA201992883A1 (ru) 2020-05-08
UA127967C2 (uk) 2024-02-28
NZ758651A (en) 2024-11-29
US10793634B2 (en) 2020-10-06
AU2018279184A1 (en) 2019-11-21
US20240101689A1 (en) 2024-03-28
JP2023093621A (ja) 2023-07-04
IL271067B2 (en) 2024-06-01
KR20200017421A (ko) 2020-02-18
PH12019502694A1 (en) 2020-07-13
CL2019003557A1 (es) 2020-05-04
PE20200173A1 (es) 2020-01-24
TW201920271A (zh) 2019-06-01
BR112019023742A2 (pt) 2020-06-09
CN110719916A (zh) 2020-01-21
IL271067B1 (en) 2024-02-01
CO2019013718A2 (es) 2020-01-17
US11866501B2 (en) 2024-01-09
SG11201911814UA (en) 2020-01-30
MY202315A (en) 2024-04-23
IL271067A (en) 2020-01-30

Similar Documents

Publication Publication Date Title
MA52884A (fr) Anticorps anti-il-11
IL272227A (en) Anti-tigit antibodies
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
MA53434A (fr) Anticorps anti-tigit
IL269405A (en) Anti-sirp alpha antibodies
MA47268A (fr) Anticorps anti-gpc3
EP3498840A4 (fr) Anticorps anti-lag-3
EP3423089A4 (fr) Anticorps anti-tigit
DK3625259T3 (da) Anti-sirpalpha-antistoffer
EP3661558A4 (fr) Anticorps anti-il1rap
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3334757A4 (fr) Anticorps anti-tigit
EP3297671A4 (fr) Anticorps anti-ror1
MA50352A (fr) Anticorps multispécifiques
MA46057A (fr) Anticorps anti-ctla4
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3691447A4 (fr) Anticorps anti-transthyrétine
EP3492591A4 (fr) Anticorps anti-b7-h4
DK3606961T3 (da) Garp-tgf-beta-antistoffer
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3399992A4 (fr) Anticorps autoréticulants